Stock MDNA MEDICENNA THERAPEUTICS CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Medicenna Therapeutics Corp.

Equities

MDNA

CA58490H1073

Biotechnology & Medical Research

Market Closed - Toronto S.E.
Other stock markets
 03:59:59 2024-04-18 pm EDT 		5-day change 1st Jan Change
1.67 CAD -3.47% Intraday chart for Medicenna Therapeutics Corp. -13.47% +297.62%
Apr. 16 Transcript : Medicenna Therapeutics Corp. Presents at Bloom Burton & Co. Healthcare Investor Conference 2024, Apr-16-2024 11:00 AM
Apr. 10 Medicenna Brief: Presenting Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of Phase 1/2 ABILITY-1 Study at 2024 Annual Meeting of the AACR MT

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Medicenna Therapeutics Corp.

Transcript : Medicenna Therapeutics Corp. Presents at Bloom Burton & Co. Healthcare Investor Conference 2024, Apr-16-2024 11:00 AM
Medicenna Brief: Presenting Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of Phase 1/2 ABILITY-1 Study at 2024 Annual Meeting of the AACR MT
Medicenna Therapeutics Presents Separate Updated Results and Preclinical Data; Shares Lost Near 12% Today MT
Medicenna Brief: Comes After Its Shares Lost Near 12% today; Earlier Today Said Presented Updated Preclinical Data On MDNA113, A First-In-Class, Targeted And Masked Bi-Functional Anti-PD1-IL2 Superkine MT
Medicenna Brief: Says Presented Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study MT
Medicenna Therapeutics Corp. Presents Updated Results of Single Agent MDNA11 Anti-Tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study CI
Medicenna Therapeutics Down 11% as it Presents Updated Preclinical Data on MDNA113 at AACR 2024 MT
Medicenna Brief: Says to Provide Clinical Update on MDNA11 ABILITY-1 Trial at Upcoming American Association for Cancer Research Annual Meeting MT
Medicenna to Provide Clinical Update on the Mdna11 Ability-1 Trial At the Upcoming American Association for Cancer Research Annual Meeting CI
Medicenna Reports Q3 Net Loss $5.0 Million MT
Medicenna Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Medicenna Brief: Net loss for the quarter ended December 31, 2023, was $5.0 million or ($0.07) per share compared to a net loss of $1.1 million or ($0.02) per share for the quarter ended December 31, 2022 MT
Medicenna Says First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda in Patients with Advanced Solid Tumors MT
Medicenna Brief: Announcing First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA (pembrolizumab) in Patients with Advanced Solid Tumors MT
Medicenna Therapeutics Corp. Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda® (Pembrolizumab) in Patients with Advanced Solid Tumors CI
Medicenna Commences Enrollment in ABILITY-1 Study Combining MDNA11 with Pembrolizumab MT
Medicenna Brief: Commencing Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab MT
Medicenna Therapeutics Corp. Announces Initiation of Enrollment in Combination Arm of Phase 1/2 ABILITY Study Evaluating MDNA11 with Merck?s Pembrolizumab CI
Medicenna Therapeutics Extends Period to Exercise Certain Warrants; Down 1.2% MT
Medicenna Therapeutics Extends Period to Exercise Certain Warrants MT
Medicenna Brief: Announcing Trading on the OTCQB Under the Symbol MDNAF MT
Medicenna Announces "Compelling" Survival Benefit From Phase 2b Study in Recurrent Glioblastoma at NeuroOncology Meeting MT
Medicenna Therapeutics Corp. Announces A Poster Presentation and an Oral Summary Highlighting Long-term Follow-up Up Results from the Phase 2b Clinical Trial of Bizaxofusp CI
Medicenna Reports Q2 Net Loss of $0.05 Per Share; Cash Runway Extended Into Q1 of Calendar 2025 MT
Medicenna Therapeutics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI

Chart Medicenna Therapeutics Corp.

Chart Medicenna Therapeutics Corp.
More charts

Company Profile

Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program is designed to enhance the ability of Superkines to treat immunologically cold tumors.
Sector
Biotechnology & Medical Research
Calendar
2024-06-25 - Q4 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.67 CAD
Average target price
9 CAD
Spread / Average Target
+438.92%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MEDICENNA THERAPEUTICS CORP. Stock Medicenna Therapeutics Corp.
+297.62% 84.58M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.82% 41.35B
LONZA GROUP AG Stock Lonza Group AG
+44.25% 40.38B
MODERNA, INC. Stock Moderna, Inc.
+2.56% 39.05B
CELLTRION, INC. Stock Celltrion, Inc.
-12.11% 26.67B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+3.09% 24.07B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.16% 18.36B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+22.12% 11.6B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.74% 11.68B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.75% 11.15B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. MDNA Stock
  4. News Medicenna Therapeutics Corp.
  5. Medicenna Therapeutics : Oppenheimer Starts Medicenna Therapeutics at Outperform With $12 Price Target